Report

Global human papillomavirus vaccine market size was valued at USD 4.58 billion in 2023 which is expected to reach USD 9.11 billion in 2031 with a CAGR of 8.99% for the forecast period between 2024 and 2031. Several factors are driving the global human papillomavirus vaccine market such as growing awareness about the importance of HPV vaccination, rising prevalence of cervical cancer and other diseases linked to HPV infection, initiatives, and vaccination programs launched by the governments, and technological advancements in vaccine development.
Governments and healthcare organizations across the globe have taken proactive steps to raise awareness about the advantages of HPV vaccination and execute vaccination campaigns, focusing on young adolescents. Consequently, the demand for HPV vaccines has consistently risen, showcasing the increasing acceptance of vaccination as a vital weapon in combatting HPV infections and related diseases.
Furthermore, the market's expansion has been bolstered by technological advancements in vaccine development, giving rise to the introduction of advanced HPV vaccines with improved efficacy and safety characteristics. The global human papillomavirus vaccine market remains a focal point for substantial investments from pharmaceutical companies and research institutions. Their objective is to develop groundbreaking vaccine formulations and enhance accessibility, ensuring that a larger population can benefit from HPV vaccination.
Nigeria incorporated the human papillomavirus (HPV) vaccine into its regular vaccination program in October 2023 to vaccinate 7.7 million girls. It is the highest number of HPV vaccinations given to patients in a single round in the African continent. The vaccine is very effective at preventing infection with HPV types 16 and 18, which are known to be the cause of at least 70% of cervical cancers, which will be given to girls between the ages of 9 and 14 in a single dosage.
High Prevalence of Cervical Cancer
The global human papillomavirus vaccine market is highly affected by the prevalence of cervical cancer. Worldwide, cervical cancer ranks as the fourth most prevalent cancer among women. More than 58% of cervical cancer cases worldwide were found in Asia, with 20% occurring in Africa, 10% in Europe, and 10% in Latin America. Similarly, it was predicted that Asia accounted for 58% of cervical cancer deaths, followed by Africa (22%), Latin America (9%), and other regions. China accounted for 18% of cervical cancer patients and India accounted for 21%, whereas mortality rates were 17% in China and 23% in India. The age-standardized incidence of cervical cancer was at its lowest in Western Asia, with 4.1 cases per 100,000 women-years.
Incidence rates were relatively low in Oceania, Northern America, and most regions of Europe, except for some countries in central and eastern Europe, such as Romania (22.6) and Bulgaria (18.0). Mortality rates showed a similar pattern to incidence, displaying significant variations across regions. Eastern Africa had the highest mortality rates at 28.6 deaths per 100,000 women years, while Western Europe reported the lowest mortality rates.
Increasing Investments in Research and Development
Over the past few years, there has been a notable increase in research and development investments in the global human papillomavirus vaccine market. The surge in funding reflects the growing recognition of the critical role these vaccines play in preventing HPV infections and associated diseases. To drive advancements in HPV vaccine technology, formulation, and distribution; governments, pharmaceutical companies, and research institutions worldwide have formed collaborations with different objectives.
The Gavi Board, in December 2022, approved the revitalization of the Alliance's HPV vaccination program, earmarking an investment of over USD 600 million by the end of 2025. With substantial funding, the Alliance has set a commendable objective of reaching more than 86 million girls by 2025 and preventing 1.4 million potential deaths from cervical cancer in the future.
Government Initiatives
Governments across the globe have acknowledged the importance of addressing the impact of cervical cancer and have initiated various initiatives to combat this virus. Initiatives taken by the government have helped in the growth of the global human papillomavirus vaccine market. Governments have implemented national cervical cancer screening programs, offering regular screening tests like pap smears or HPV testing, to detect pre-cancerous lesions in their early stages. These programs play a vital role in reducing the occurrence of cervical cancer by facilitating timely interventions. For instance, in the interim budget for 2024-2025, Union Finance Minister of India declared that the government intended to vaccinate all girls aged 9-14 against cervical cancer. It occurred more than a year after the vaccine's introduction under the Universal Vaccination Programme (UIP) was recommended by the National Technical Advisory Group on Immunization (NTAGI), the highest vaccination advisory body of the national government.
Increasing Demand for Bivalent Vaccine
Rising demand for bivalent vaccines has caused an increase in the growth of the global human papillomavirus vaccine market. The bivalent human papillomavirus (HPV) vaccine has become a pivotal weapon in the battle against cervical cancer and other HPV-related diseases. With its focus on targeting specific HPV strains responsible for a large proportion of cervical cancer cases, the vaccine has garnered considerable interest and recognition for its demonstrated efficacy and safety.
The HPV bivalent vaccine is administered to girls and young women aged 9 to 25. It is important to note that individuals can receive this vaccine even if they have previously tested positive for HPV or have had an abnormal pap smear in the past. In May 2022, China's National Medical Products Administration (NMPA) granted approval for a two-dose vaccine schedule of Cervarix, a bivalent vaccine developed by GlaxoSmithKline PLC, a British multinational pharmaceutical and biotechnology company. The approval was for the prevention of cervical cancer, cervical intraepithelial neoplasia, and adenocarcinoma in-situ linked to oncogenic Human Papillomavirus (HPV) types 16 and 18.
Growing Demand for Human Papillomavirus Vaccine for Cervical Cancer
In response to significant public health challenges, the development of HPV vaccines has emerged as a crucial preventive strategy against cervical cancer and other HPV-related illnesses, which has led to the growth of global human papillomavirus vaccine market. Their introduction of HPV vaccine has sparked significant interest in preventive healthcare, presenting a promising approach to alleviate the burden of cervical cancer and its impact. Through rigorous research and clinical trials, these vaccines have demonstrated their efficacy and safety, paving the way for their widespread incorporation into national immunization programs. Walvax Biotechnology, a Chinese drug developer, received approval to launch its recombinant bivalent human papillomavirus vaccine in China in March 2022. This vaccine has demonstrated efficacy in preventing cervical cancer caused by specific HPV strains, making it a significant milestone in the fight against human papillomavirus.
Asia-Pacific to Dominate the Market in Terms of Prevalence and Vaccination Drives
Cervical cancer is highly prevalent in Asian nations. Asia accounted for an estimated 58% of all cervical cancer cases worldwide. Several measures are being taken by governments in Asia-Pacific to address this problem. It is advised to receive the HPV vaccine as part of a comprehensive and well-coordinated plan to prevent HPV-related diseases, including cervical cancer. While India and Indonesia have implemented HPV, countries, such as Bhutan, Sri Lanka, Thailand, and Maldives have it on a national scale. HPV demonstration programs have been completed in Bangladesh and Nepal, and plans are in motion for a countrywide introduction. The introduction plans for Myanmar have been authorized. Crowell & Moring International formed the Asia-Pacific Women's Cancer Coalition in June 2023, partnering with Roche, TogetHER for Health, CAPED, and Jhpiego to increase awareness about the rise in breast and cervical cancer incidence in Asia-Pacific. To assist nations in reaching their national goals for cancer prevention and control, the coalition focuses on finding opportunities and filling up the gaps.
Future Market Scenario (2024 - 2031F)
� The increased prevalence of HPV-related diseases, including cervical, anal, and oropharyngeal malignancies, is driving the demand for HPV vaccines globally.
� Strategic approvals and activities to increase vaccine coverage are taking place in global human papillomavirus vaccine market.
� In the global human papillomavirus vaccine market, major pharmaceutical companies are concentrating on developing new products and improving vaccination efficiency through research and development.
� Cervical cancer is more prevalent in developing countries. Due to increasing urbanization, the prevalence of cervical cancer will increase leading to an increase in demand for HPV in developing countries coupled with awareness campaigns launched by governments.
Key Players Landscape and Outlook
Over the past few years, global human papillomavirus vaccine market has experienced a significant trend of mergers and collaborations among pharmaceutical companies and research institutions. These strategic partnerships have emerged as powerful drivers in advancing HPV vaccine development and distribution, with the shared goal of addressing the burden of HPV infections and associated diseases on a worldwide scale. The increasing demand for HPV vaccines, fueled by the growing awareness of their preventive benefits against cervical cancer and other HPV-related illnesses, has spurred key industry players to unite their efforts. Through mergers and collaborations, these companies combine their resources, expertise, and research capabilities to accelerate vaccine development, enhance formulations, and extend their reach in global human papillomavirus vaccine market.
For instance, in December 2022, NusaGard, a human papillomavirus (HPV) vaccination, was launched by Bio Farma Induk Holding BUMN Pharmacy in partnership with Merck Sharp & Dohme (MSD) and its subsidiaries, Kimia Farma and Indofarma.